In March 2019, MAPS Public Benefit Corporation (MAPS PBC) received a clinical hold letter from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program …
Twenty-nine participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United …
On February 5, 2019, a MAPS-sponsored Phase 3 study site for MDMA-assisted psychotherapy for PTSD was initiated in Be’er Ya’akov, Israel. Led by Principal Investigator Jana Yakirevitch, M.D., this …
On February 3, 2019, the Israeli Ministry of Health announced the approval of compassionate use for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), which will allow 50 patients to …
Twenty-six participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United …
This month, our Phase 3 multi-site study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is continuing to open sites for screening. Eight sites are open for screening at this time. …
In January 2019, MAPS Public Benefit Corporation (MAPS PBC) sent a formal protocol to the U.S. Food and Drug Administration (FDA) for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
Twenty-five participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United …
This month, MAPS study sites in New Orleans, Louisiana, Charleston, South Carolina, Fort Collins, and Boulder, Colorado received a shipment of pharmaceutical-grade MDMA, made under current Good Manufacturing …
Twenty-three participants have completed treatment in our Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at planned Phase 3 sites across the United …
Our FDA-regulated Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD have officially launched. These trials are taking place at 14 locations across the United States, Canada, and Israel. On …
MAPS-sponsored researchers have completed study initiation visits for FDA-regulated Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at five United States locations: …
